Amlodipine/atorvastatin

Drug Profile

Amlodipine/atorvastatin

Alternative Names: Amlodipine besylate/atorvastatin calcium; Astucor; Atorvastatin/amlodipine; Caduet; CI-1038

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Almirall S.A.; Pfizer
  • Class Antihyperlipidaemics; Antihypertensives; Dihydropyridines; Heptanoic acids; Ischaemic heart disorder therapies; Pyrroles
  • Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hypertension

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2011 Generic equivalent available in USA
  • 08 Jul 2011 Pfizer and Astellas amend their co-promotion agreement for amlodipine/atorvastatin in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top